JIPE. VE	-			
Under the Paperwork Reduction Act of 1995, no	persons are requ	U.S. Patent and Trademark (Office; U	PTO/SB/21 (05-03) e through 04/30/2003. OMB 0651-0031 .S. DEPARTMENT OF COMMERCE n unless it displays a valid OMB control
MADERILE		Application Number		10/660,113
OIP TRANSMITTA	AL	Filing Date		September 10, 2003
FEB 1 7 2004 FORM		First Named Inventor		Kavita Shah
(to be used for all correspondence after in	nitial filing)	Group Art Unit		1645
MADEMINISTIS		Examiner Name		Unassigned
Total Number of Pages in This Submissi	on	Attorney Docket Number		36-001720US
	ENCLOS	SURES (check all that app	oly)	
Fee Transmittal Form	Assignm (for an A	nent Papers Application)		After Allowance Communication to Group
Fee Attached	Drawing	(s)		Appeal Communication to Board of Appeals and Interferences
Amendment / Response	Licensir	g-related Papers		Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
After Final	Petition and Acc	Routing Slip (PTO/SB/69) companying Petition		Proprietary Information
Affidavits/declaration(s)		to Convert to a nal Application		Status Letter
Extension of Time Request	Power of Change Address	f Attorney, Revocation of Correspondence	X	Additional Enclosure(s) (please identify below):
Express Abandonment Request	Termina	l Disclaimer		PTO-1449 form, Cited References and receipt
X Information Disclosure Statement	Small E	ntity Statement		acknowledgment postcard
Condition Compatibility		t for Refund		
Document(s) Ple	ease charge D s paper or dur	o Charge Deposit Account eposit Account No. 50-0893 f ing the pendency of this appli of the documents enclosed.	or any cation,	additional fees associated with including any extensions of time
Response to Missing Parts under 37 CFR 1.52 or 1.53	Remarks			
SIGNATURE	OF APPLI	CANT, ATTORNEY, OR	AGEN	Т
Firm or Individual name Angela P. Horne, I	Ph.D., Reg.	No. 41,079, Quine Intel	lectua	il Property Law Group, P.C.
Signature Augula P. O.	Journ	PUD		
Signature Augula P. O. Date February 1.	3, 2004	4		
		ATE OF MAILING		

	CER	TIFICATE OF M	AILING		
I hereby certify that this corre envelope addressed to: Comm	spondence is being deposited hissioner for Patents, P.O. B	d with the United States ox 1450, Alexandria, V.	Postal Service with: A 22313-1450 on the	date chown below	class mail in an
Typed or printed name	Evelyn Gomez	h			,
Signature	Eller	B	Date	Februar	4 13,200



I hereby certify that this correspondence is being deposited with the United States Postal Service first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450

Alexandria, VA 22313-1450, on <u>February 13</u>

QUINE INTELLECTUAL PROPERTY LAW GROUP, P.C.

Evelyn Gomez

Attorney Docket No. 36-001720US Client Ref. No. P0046US20

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Kavita Shah, et al.

Application No.: 10/660,113

Filed: September 10, 2003

For: HIGHLY SPECIFIC MODULATORS

OF GTPASES FOR TARGET

VALIDATION

Examiner: Unassigned

Art Unit: 1645

INFORMATION DISCLOSURE

STATEMENT UNDER 37 CFR § 1.97 and

§ 1.98

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

The references cited on attached form PTO-1449 are being called to the attention of the Examiner. Copies of the references are enclosed. It is respectfully requested that the cited information be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

Kavita Shah, et al.

Application No.: 10/660,113

Page 2

Applicant believes that <u>no fee is required</u> for submission of this statement, since it is being submitted prior to the first Office Action on the merits per 37 CFR 1.97(b)(3). However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 50-0893. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,

Myler P. Horry AV Angela P. Horne, Ph.D.

Reg. No. 41,079

QUINE INTELLECTUAL PROPERTY LAW GROUP, P.C.

P.O. BOX 458 Alameda, CA 94501 (510) 337-7871

Fax (510) 337-7877

PTO/SB/08A (04-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

TRACTINFORMATION DISCLOSURE
TO SENT BY APPLICANT

Substitute for form 1449A-B/PTO

(use as many sheets as necessary)

		omplete if Known		
	· · · · · · · · · · · · · · · · · · ·			
	Application Number	10/660,113		
	Filing Date	September 10, 2003		
First Named Inventor		Kavita Shah		
	Group Art Unit	1645		
	Examiner Name	Unassigned		
	Attorney Docket Number	36-001720US		
	Date Submitted	February 13, 2004		

	U.S. PATENT DOCUMENTS					
Examiner Initials	Cite No.	U.S. Patent Di Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, lines, Where Relevant Passages or Relevant Figures Appeal
	1	6,390,821	BI	Princeton Unversity	05-21-2002	

		-		FOREIGN	N PATENT DOCUMEN	TS		
		F	Foreign Patent Docum			Date of Publication	Pages, Columns, Lines,	
Examiner Initials	Cite No.	Office	Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	of Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear	Т
								
	l							

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Т
	2	BENARD et al., "Potential Drug Targets: Small GTPases that Regulate Leukocyte Function" Trends Pharmacol. Science, 20:365-370 (1999).	
	3	BISHOP et al., "Design of Allele-Specific Inhibitors to Probe Protein Kinase Signaling" Current Biology, 8:257-266 (1998).	
	4	BISHOP et al., "Generation of Monospecific Nanomolar Tyrosine Kinase Inhibitors via a Chemical Genetic Approach", J. Am. Chem. Soc., 121:627-631 (1999).	
	5	BISHOP et al., "A chemical switch for inhibitor-sensitive alleles of any protein kinase" Nature, 407: 395-401 (2000).	
	6	BISHOP et al., "Unnatural Ligands for Engineered Proteins: New Tools for Chemical Genetics" Annu. Rev. Biophys. Biomol. Struct., 29: 577-606 (2000).	

Examiner	Date	
Signature	 Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

PTO/SB/08A (04-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE o a collection of information unless it contains a valid OMB control number.

Under the Paperwork Reduction Act of 1995, no persons a	are required to respond to a collection of	information unless it contains a valid OMB control number.
Substitute for form 1449A-B/PTO	C	omplete if Known
OIPE	Application Number	10/660,113
INFORMATION DISCLOSURE	Filing Date	September 10, 2003
STATEMENT BY APPLICANT	First Named Inventor	Kavita Shah
FEB 1 7 2004 (1)	Group Art Unit	1645
	Examiner Name	Unassigned
(use as fijany sheets as necessary)	Attorney Docket Number	36-001720US
Constitution of the second	Date Submitted	February 13, 2004

7	BOQUET et al., "Rho GTP-Binding Proteins as Targets for Microbial Pathogens" Prog. Mol. Subcell. Biol., 22:183-199 (1999).
8	BOS, "Ras Oncogenes in Human Cancer: A Review" Cancer Res., 49:4682-4689 (1989).
9	BOURNE et al., "The GTPase Superfamily: Conserved Structure and Molecular Mechanism" Nature, 349:117-27 (1991).
10	BARBACID "Ras Oncogenes: Their Role in Neoplasia" Eur. J. Clin. Invest., 20:225-235 (1990).
11	CARROLL et al., "Role of Rab9 GTPase in Facilitating Receptor Recruitment by TIP47", Science, 292:1373-1376 (2001).
12	CARROLL et al., "Chemical Inhibition of the Pho85 Cyclin-Dependent Kinase Reveals a Role in the Environmental Stress Response", Proc. Natl. Acad. Sci. USA, 98:22:12578-12583 (2001).
13	COOL et al., "The Ras Mutant D119N is Both Dominant Negative and Activated" Mol. Cell. Biol., 19: 6297-6305 (1999).
14	COWARD et al., "Controlling Signaling with a Specifically Designed Gi-Coupled Receptor" Proc. Natl. Acad. Sci. USA, 95: 352-357 (1998).
15	DE GUNZBURG, "Proteins of the Ras Pathway as Novel Potential Anticancer Therapeutic Targets" Cell Biol. Toxicol., 15:345-358 (1999).
16	DOWNWARD, "Targeting Ras Signaling Pathways in Cancer Therapy" Nat. Rev. Cancer, 3:11-22 (2003).
17	GILLESPIE et al., "Engineering of the Myosin-I β Nucleotide-binding Pocket to Create Selective Sensitivity to N^6 -Modified ADP Analogs", The Journal of Biological Chemistry, 274:31373-31381 (1999).
18	HABELHAH et al., "ERK Phosphorylation Drives Cytoplasmic Accumulation of HnRNP-K and Inhibition of mRNA Translation", Nature Cell Biology, 3:325-330 (2001).
19	HABELHAH et al., "Identification of New JNK Substrate Using ATP Pocket Mutant JNK and a Corresponding ATP Analogue", The Journal of Biological Chemistry, 276:2:18090-18095 (2001).

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

PTO/SB/08A (04-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
o a collection of information unless it contains a valid OMB control number.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.				
Substitute for form 1449A-B/PTO	Complete if Known			
_	Application Number	10/660,113		
P INFORMATION DISCLOSURE	Filing Date	September 10, 2003		
STATEMENT BY APPLICANT	First Named Inventor	Kavita Shah		
(A)	Group Art Unit	1645		
2004 8	Examiner Name	Unassigned		
[ijse as many sheets as necessary)	Attorney Docket Number	36-001720US		
	Date Submitted	February 13, 2004		

inia di di		
	20	HOLT et al., "A Chemical-Genetic Strategy Implicates Myosin-1c in Adaptation by Hair Cells" Cell, 108: 371-3 81 (2002).
	21	HWANG & MILLER, "A Mutation that Alters the Nucleotide Specificity of Elongation Factor Tu, a GTP Regulatory Protein" J. Biol. Chem., 262:13081-5 (1987).
	22	LIN et al., "Design of Allele-Specific Protein Methyltransferase Inhibitors" J. Am. Chem. Soc., 123: 11608-13 (2001).
	23	LIU et al., "A Molecular Gate which Controls Unnatural ATP Analogue Recognition by the Tyrosine Kinase v-Src", Bioorganic & Medicinal Chemistry, 6:1219-1226 (1998).
	24	LIU et al., "Engineering Src Family Protein Kinases with Unnatural Nucleotide Specificity", Chemistry & Biology, 5:91-101 (1998).
	25	LIU et al., "Src-Abl Tyrosine Kinase Chimeras: Replacement of the Adenine Binding Pocket of c-Abl with v-Src to Swap Nucleotide and Inhibitor Specificities", Biochemistry, 39:14400-14408 (2000).
	26	NEVES et al., "G Protein Pathways", Science, 296:1636-1638 (2002).
	27	PEET et al., "Engineering Novel Specificities for Ligand-Activated Transcription in the Nuclear Hormone Receptor RXR" Chem. Biol., 5:13-21 (1998).
	28	POLAKIS AND MCCORMICK, "Structural Requirements for the Interaction of p21 ^{ras} with GAP, Exchange Factors, and its Biological Effector Target" J. Biol. Chem., 268:9157-9160 (1993).
	29	SCHREIBER, "Chemical Genetics Resulting from a Passion for Synthetic Organic Chemistry" Bioorganic Med. Chem., 6: 1127-52 (1998).
	30	SHAH & SHOKAT, "A Chemical Genetic Screen for Direct v-Src Substrates Reveals Ordered Assembly of a Retrograde Signaling Pathway" Chemistry & Biology, 9: 35-47 (2002).
	31	SHAH et al., "Engineering Unnatural Nucleotide Specificity for Rous Sarcoma Virus Tyrosine Kinase to Uniquely Label its Direct Substrates" Proc. Natl. Acad. Sci. USA, 94: 3565-3570 (1997).
	32	SHOKAT & VELLECA, "Novel Chemical Genetic Approaches to the Discovery of Signal Transduction Inhibitors" Drug Discovery Today, 7: 872-879 (2002).

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

PTO/SB/08A (04-03)
Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
o a collection of information unless it contains a valid OMB control number.

Under the Paperwork Reduction Act of 1995, no persons a	ire required to respond to a collection of	Information unless it contains a valid ONB control number.
Substitute for form 1449A-B/PTO	Complete if Known	
	Application Number	10/660,113
P ENFORMATION DISCLOSURE	Filing Date	September 10, 2003
STATEMENT BY APPLICANT	First Named Inventor	Kavita Shah
i di	Group Art Unit	1645
1 7 2004 (2)	Examiner Name	Unassigned
(use as many sheets as necessary)	Attorney Docket Number	36-001720US
*	Date Submitted	February 13, 2004

ALC: NO.			
	33	SPENCER et al., "Controlling Signal Transduction with Synthetic Ligands" Science, 262:1019-1024 (1993).	
	34	SPRANG, "G Proteins Mechanisms: Insights from Structural Analysis" Annual Rev. Biochem., 66:639-678 (1997).	
	35	ULRICH et al., "Towards the Engineering of an Orthogonal Protein Kinase/Nucleotide Triphosphate Pair" Tetrahedron, 56:9495-9502 (2000).	
	36	VENTER et al., "The Sequence of the Human Genome", Science, 291:1304-51 (2001).	
	37	VETTER & WITTINGHOFER, "The Guanine Nucleotide-Binding Switch in Three Dimensions" Science, 294:1299-3304 (2001).	
	38	WALTER et al., "The Oncogenic Activation of Human p21 ^{ras} by a Novel Mechanism" Science, 233:649-652 (1986).	
	39	WEIJLAND et al., "Elongation Factor Tu D138N, a Mutant with Modified Substrate Specificity, as a Tool to Study Energy Consumption in Protein Biosynthesis" Biochemistry, 33:10711-10717 (1994).	
	40	WEIJLAND et al., "Toward a Model for the Interaction Between Elongation Factor Tu and the Ribosome", Science, 259:1311-1314 (1993).	
	41	WOLFMAN, "Ras Isoform-Specific Signaling: Location, Location, Location" Science's STKE, 96:1-4 (2001).	
	42	YU et al., "Characterization of a Goα Mutant That Binds Xanthine Nucleotides", Journal of Biological Chemistry, 272:18015-18019 (1997).	

Examiner	Date
Signature	Considered

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.